These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36018237)

  • 21. A Focused Update on Tardive Dyskinesia.
    Blanchet PJ
    Can J Neurol Sci; 2020 Nov; 47(6):747-755. PubMed ID: 32624027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
    Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder.
    McIntyre RS; Calabrese JR; Nierenberg AA; Farahmand K; Yonan C; Siegert S; Burke J
    J Affect Disord; 2019 Mar; 246():217-223. PubMed ID: 30583148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implications of Antipsychotic Use: Antipsychotic-Induced Movement Disorders, with a Focus on Tardive Dyskinesia.
    Dilks S; Xavier RM; Kelly C; Johnson J
    Nurs Clin North Am; 2019 Dec; 54(4):595-608. PubMed ID: 31703784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Antipsychotic Type and Dose Changes on Tardive Dyskinesia and Parkinsonism Severity in Patients With a Serious Mental Illness: The Curaçao Extrapyramidal Syndromes Study XII.
    Mentzel CL; Bakker PR; van Os J; Drukker M; Matroos GE; Hoek HW; Tijssen MA; van Harten PN
    J Clin Psychiatry; 2017 Mar; 78(3):e279-e285. PubMed ID: 28199071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparing the risk of tardive dyskinesia in older adults with first-generation and second-generation antipsychotics: a systematic review and meta-analysis.
    O'Brien A
    Int J Geriatr Psychiatry; 2016 Jul; 31(7):683-93. PubMed ID: 26679687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deutetrabenazine in the treatment of tardive dyskinesia.
    Niemann N; Jimenez-Shahed J
    Neurodegener Dis Manag; 2019 Apr; 9(2):59-71. PubMed ID: 30702019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis.
    Carbon M; Hsieh CH; Kane JM; Correll CU
    J Clin Psychiatry; 2017 Mar; 78(3):e264-e278. PubMed ID: 28146614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tardive Dyskinesia: Treatment Update.
    Arya D; Khan T; Margolius AJ; Fernandez HH
    Curr Neurol Neurosci Rep; 2019 Aug; 19(9):69. PubMed ID: 31420757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis.
    Patterson-Lomba O; Ayyagari R; Carroll B
    BMC Neurol; 2019 Jul; 19(1):174. PubMed ID: 31325958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clozapine Monotherapy as a Treatment for Antipsychotic-Induced Tardive Dyskinesia: A Meta-Analysis.
    Mentzel TQ; van der Snoek R; Lieverse R; Oorschot M; Viechtbauer W; Bloemen O; van Harten PN
    J Clin Psychiatry; 2018 Sep; 79(6):. PubMed ID: 30257080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tardive Dyskinesia-like Syndrome Due to Drugs that do not Block Dopamine Receptors: Rare or Non-existent: Literature Review.
    D'Abreu A; Friedman JH
    Tremor Other Hyperkinet Mov (N Y); 2018; 8():570. PubMed ID: 30191087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hospital utilization rates following antipsychotic dose reduction in mood disorders: implications for treatment of tardive dyskinesia.
    Caroff SN; Mu F; Ayyagari R; Schilling T; Abler V; Carroll B
    BMC Psychiatry; 2020 Jul; 20(1):365. PubMed ID: 32652964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Valbenazine in the treatment of tardive dyskinesia.
    Witek N; Comella C
    Neurodegener Dis Manag; 2019 Apr; 9(2):73-81. PubMed ID: 30724115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Revisiting Tardive Dyskinesia: Focusing on the Basics of Identification and Treatment.
    Citrome L; Saklad SR
    J Clin Psychiatry; 2020 Feb; 81(2):. PubMed ID: 32078259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment Strategies for Tardive Dyskinesia.
    Kremens DE
    J Clin Psychiatry; 2019 Dec; 81(1):. PubMed ID: 31880872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Valbenazine as the first and only approved treatment for adults with tardive dyskinesia.
    Sarva H; Henchcliffe C
    Expert Rev Clin Pharmacol; 2018 Mar; 11(3):209-217. PubMed ID: 29338466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
    Josiassen RC; Kane JM; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):61-68. PubMed ID: 28839341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 4: Case Report Data.
    Macaluso M; Flynn A; Preskorn S
    J Psychiatr Pract; 2016 May; 22(3):203-20. PubMed ID: 27123800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assesment of Risk Factors for Tardive Dyskinesia.
    Vardar MK; Ceylan ME; Ünsalver BÖ
    Psychopharmacol Bull; 2020 Jul; 50(3):36-46. PubMed ID: 32733110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.